How Real-World Evidence Is Shaping Treatment Decisions in ER+ Breast Cancer

Hope S. Rugo, MD, and Seth Wander, MD, PhD, discuss treatment selection after CDK4/6 inhibitor progression in advanced ER-positive breast cancer.

Experts discuss the integration of oral SERDs like elacestrant into clinical practice, highlighting their benefits for ESR1 mutant populations in breast cancer treatment.

Explore the impact of elacestrant on ESR1-mutated breast cancer, revealing real-world data insights and genomic factors influencing treatment outcomes.

Researchers analyze real-world data on ESR1-mutated breast cancer treatments, revealing promising outcomes and insights for patient care strategies.

Experts discuss the implications of the SERENA-6 trial, highlighting the potential benefits of early oral SERD deployment in breast cancer treatment.

Experts discuss the future of breast cancer treatment, emphasizing personalized approaches and the potential of new oral therapies to improve outcomes.